Our understanding of the molecular pathogenesis of myeloid malignancies, most notably acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), has largely resulted from the identification and characterization of recurrent chromosomal translocations. 1 However, in many patients with myeloproliferative neoplasms (MPNs) and chronic myelomonocytic leukemia (CMML), recurrent clonal cytogenetic abnormalities are not observed. More recently, DNA resequencing studies of candidate genes, 2 gene families, 3,4 and the cancer genome 5 in MPN, CMML, and AML have identified somatic mutations in FLT3, 6 JAK2, [7] [8] [9] [10] [11] [12] [13] 14, 15 and the RAS family of oncogenes. 16 These discoveries demonstrate activation of signal transduction pathways is a common pathogenic event in myeloid malignancies and have led to the development of molecularly targeted therapies. However, with the exception of CML, these therapies have yet to substantively improve outcomes for patients with myeloid malignancies. 17, 18 This may reflect insufficient target inhibition, or, alternatively, this may indicate incomplete dependence on these activated pathways resulting from the presence of additional somatic mutations with prognostic, therapeutic, and biologic relevance.
Introduction
Our understanding of the molecular pathogenesis of myeloid malignancies, most notably acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), has largely resulted from the identification and characterization of recurrent chromosomal translocations. 1 However, in many patients with myeloproliferative neoplasms (MPNs) and chronic myelomonocytic leukemia (CMML), recurrent clonal cytogenetic abnormalities are not observed. More recently, DNA resequencing studies of candidate genes, 2 gene families, 3, 4 and the cancer genome 5 in MPN, CMML, and AML have identified somatic mutations in FLT3, 6 JAK2, [7] [8] [9] [10] [11] [12] [13] MPL, 14, 15 and the RAS family of oncogenes. 16 These discoveries demonstrate activation of signal transduction pathways is a common pathogenic event in myeloid malignancies and have led to the development of molecularly targeted therapies. However, with the exception of CML, these therapies have yet to substantively improve outcomes for patients with myeloid malignancies. 17, 18 This may reflect insufficient target inhibition, or, alternatively, this may indicate incomplete dependence on these activated pathways resulting from the presence of additional somatic mutations with prognostic, therapeutic, and biologic relevance.
The role of TET (Ten-Eleven Translocation) family gene members in hematopoietic transformation was thought to be restricted to the involvement of TET1 as a translocation partner MLL-translocated AML, until the recent identification of inactivating mutations in TET2 in MPN and MDS patients. 19 We therefore sought to evaluate a large set of MPN, CMML, and AML samples for somatic TET2 alterations. We sequenced all coding exons of TET2 in 408 paired tumor/normal samples and then assessed the frequency of somatic TET2 mutations in 606 patients with MPN, CMML, and AML. We also investigated whether deletion or epigenetic inactivation of TET2 are observed in MPN and evaluated MPN patients for somatic mutations in TET1 and TET3. 
Methods

Patients
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Memorial Sloan-Kettering Cancer Center for these studies, and informed consent was provided according to the Declaration of Helsinki.
Sequence analysis of TET1, TET2, and TET3
DNA resequencing of all coding exons of TET1-3 was performed (primers/ conditions are listed in supplemental Table 1 , available on the Blood website; see the Supplemental Materials link at the top of the online article). Nonsynonymous alterations not present in single nucleotide polymorphism (database [db]SNP) were annotated as somatic mutations or SNPs based on sequence analysis of matched germ line DNA. Nonsynonymous alterations not in dbSNP nor determined to be somatic in paired samples or in recently reported data 19 were censored. All somatic mutations were validated by resequencing nonamplified DNA.
Copy number analysis of TET1, TET2, and TET3
A total of 207 MPN tumor samples were analyzed using Affymetrix 250K StyI Arrays. 20 The JAK2V617F-mutant AML cell lines HEL and SET2 were analyzed using Affymetrix 6.0 SNP Arrays.
Methylation-specific polymerase chain reaction
Methylation of 2 CpG islands in the promoter region of TET2 was assessed in 37 MPN patients and 4 JAK2V617F-positive leukemia cell lines (SET2, MBO2, HEL, UKE1). Methylation-specific polymerase chain reaction was performed as previously described (primers are listed in supplemental Table 1 ). 21 
Statistics
Statistical analyses were performed using MedCalc (MedCalc).
Results and discussion
Sequence analysis of all coding exons of TET2 in 408 paired tumor/normal samples identified 8 frameshift, 12 nonsense, and 37 nonsynonymous alterations not present in dbSNP. Analysis of germ line DNA distinguished between 31 somatic missense mutations and 6 unannotated SNPs (Table 1 ; supplemental Figure  1 ); all unannotated SNPs were observed in matched normal tissue in at least 2 samples. All frameshift and nonsense mutations were not present in matched normal tissue. The strategy of paired sequencing of normal and tumor tissue is critical for accurate annotation of candidate mutations as 2 novel SNPs, which were recently reported as TET2 mutations (Q1084P and Y867H) 22 were present in the germ line in multiple patient samples consistent with their being unannotated SNPs. After defining the spectrum of somatic TET2 mutations in paired tumor/normal samples, we determined the frequency of TET2 mutations in MPN (7.6%, including 9.8% polycythemia vera, 4.4% essential thrombocythemia, and 7.7% primary myelofibrosis), CMML (42.1%), AML (12.1%), and acute megakaryoblastic leukemia (3.6%). We identified biallelic/homozygous TET2 mutations in 1 of 354 MPN patients and in 7 of 69 CMML patients (P Ͻ .001, Fisher exact test). Sequencing of TET2 in 48 affected members from 28 MPN kindreds identified somatic TET2 mutations in 7 affected persons. We also identified 4 germ line nonsynonymous variants in affected members of MPD kindreds present in dbSNP that could represent rare familial MPN alleles. However, 3 of these 4 SNPs were observed in only some affected members of kindred but not others, and the fourth variant (M1701I) is observed in many sporadic MPN, CMML, and AML cases. Somatic TET2 mutations were not noted in the 4 JAK2V617F-positive leukemic cell lines.
We did not identify methylation at either of 2 CpG islands of the TET2 promoter in 37 MPN samples or in 4 JAK2V617F-positive leukemic cell lines (supplemental Figure 2) . Copy number analysis of 207 MPN patients identified 3 patients with heterozygous deletions of one copy of the region containing TET2 (4q24), suggesting that TET2 mutations are more common than large deletions in MPN patients. Sequencing data from these 3 patients revealed that one patient had a homozygous somatic missense mutation, consistent with heterozygous mutation followed by deletion of the remaining copy of TET2 (supplemental Figure 3) . The HEL cell line had a heterozygous deletion of the TET2 locus. One MPN patient had a large deletion on chromosome 10, which included the TET1 locus (10q21.3). Furthermore, although we identified several novel SNPs in TET1 and TET3 (supplemental Novel unannotated SNPs in 4q24. SNPs were defined as missense mutations that were seen in more than one tumor and paired buccal sample.
*Somatic missense mutations that occurred in more than 2 samples.
described JAK2V617F-positive MPN predisposition haplotype (P ϭ .9). 20 We did not note a correlation between TET2 alterations and mutations in FLT3, JAK2, and RAS in CMML, nor did we observe a correlation between TET2 mutations and specific cytogenetic subgroups MLL, FLT3, CEBPA, or NPM1 mutations, or a history of antecedent MPN/MDS in AML (P Ͼ .5, Fisher exact test). However, we did note that TET2 mutations are associated with decreased overall survival in AML compared with TET2-wildtype AML patients (P ϭ .03, Figure 1D ; supplemental Table 2) . In this report, we sequenced all coding exons of TET2 to define the spectrum of somatic TET2 mutations in myeloid malignancies. The broad range of myeloid disorders linked to mutations in TET2 suggests that mutations in TET2 have a pleiotropic role in myeloid transformation. Although our data suggest that TET2 mutations may hold prognostic significance in AML, larger clinical correlative studies will be needed to more accurately assess the effect of TET2 mutations on prognosis, diagnosis, and therapeutic relevance to myeloid malignancies. Whether TET2 mutations dysregulate pathways already known to contribute to hematopoietic transformation, or represent a novel pathway, remains to be elucidated, and the role of TET family alterations in neoplasms other than myeloid malignancies is not yet known. 
